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Krista L. Lentine1,2,4*, Mark A. Schnitzler2, Huiling Xiao1,2 and Daniel C. Brennan3After publication of this article, it has come to our atten-
tion that a few corrections had not been updated. We are
publishing this erratum to highlight what has been updated
from the original article. The updates are as follows:-
Abstract – the abstract has been updated to reflect the
figures in Table 2, patient survival percentage has been
updated from 52.5 % to 52.8 %.
Table 2 – The P value for Freedom from acute rejection,
graft failure or death has been updated from 0.05 to 0.04.
Figure 3 captions were incorrect on the original article.
This has now been updated. The caption for 3b was
updated from Patient survival to Death-censored graft
survival. The caption for 3c was updated from Death
censored graft survival to Patient Survival.
The corresponding text relating to Fig. 3 has also been
updated in line with the figure changes. In the original
article it was:-
Patient survival was numerically and statistically simi-
lar in both treatment groups at 5 years and equivalent at
10 years (rATG, 52.8 %; basiliximab, 52.2 %; P = 0.92)
(Fig. 3b). Death-censored graft survival was also equivalent
in the two groups by 10 years (rATG, 68.5 %; basiliximab,
68.4 %; two-sided P = 0.80) (Fig. 3c). Combining trends
in mortality and graft failure, all-cause graft survival was
generally similar over time among participants randomized
to both trial arms, and by 10 years was 34.3 % in those
treated with rATG versus 30.9 % in those treated with
basiliximab at (two-sided P = 0.56) (Fig. 3d).* Correspondence: lentinek@slu.edu
The online version of the original article can be found under
doi:10.1186/s13063-015-0891-y.
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Death-censored graft survival was also equivalent in
the two groups by 10 years (rATG, 68.5 %; basiliximab,
68.4 %; two-sided P = 0.80) (Fig. 3b). Patient survival was
numerically and statistically similar in both treatment
groups at 5 years and equivalent at 10 years (rATG,
52.8 %; basiliximab, 52.2 %; P = 0.92) (Fig. 3c). Combining
trends in mortality and graft failure, all-cause graft sur-
vival was generally similar over time among participants
randomized to both trial arms, and by 10 years was
34.3 % in those treated with rATG versus 30.9 % in
those treated with basiliximab (two-sided P = 0.56) (Fig. 3d).
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